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Abstract
Prostate cancer (PCa) is a complex disease that disproportionately affects African Americans and other individuals of African
descent. A number of regions across the genome have been associated to PCa, most of them with moderate effects. A few
studies have reported chromosomal changes on 12p and 12q that occur during the onset and development of PCa but to
date no consistent association of the disease with chromosome 12 polymorphic variation has been identified. In order to
unravel genetic risk factors that underlie PCa health disparities we investigated chromosome 12 using ancestry informative
markers (AIMs), which allow us to distinguish genomic regions of European or West African origin, and tested them for
association with PCa. Additional SNPs were genotyped in those areas where significant signals of association were detected.
The strongest signal was discovered at the SNP rs12827748, located upstream of the PAWR gene, a tumor suppressor, which
is amply expressed in the prostate. The most frequent allele in Europeans was the risk allele among African Americans. We
also examined vitamin D related genes, VDR and CYP27B1, and found a significant association of PCa with the TaqI
polymorphism (rs731236) in the former. Although our results warrant further investigation we have uncovered a genetic
susceptibility factor for PCa in a likely candidate by means of an approach that takes advantage of the differential
contribution of parental groups to an admixed population.
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Introduction
Prostate cancer (PCa) represents a major health burden to the
US male population. In particular, African Americans are
disproportionately affected by PCa, presenting with more
advanced disease and worse prognosis than European Americans
[1]. Reasons for the disparities include a number of genetic and
environmental factors such as race, age, family history, socioeco-
nomic status and access to health care [2].
Over the years there has been an accumulation of evidence in
favour of a significant hereditary component in PCa susceptibility,
however the search for PCa genes has yielded few consistent
results. Recently, genome-wide linkage, association and admixture
mapping scans have detected risk loci on chromosomes 2p15,
3p12, 6q25, 7q21, 8q24, 10q11, 11q13, 17q12, 17q24, 19q13,
22q13 and Xp11 [3] (see also GWAS catalog: http://www.
genome.gov/gwastudies/), although polymorphic variants in these
regions seem to account for only a small proportion of the
observed genetic predisposition to PCa.
To determine whether the health inequalities between African
Americans and European Americans can be partially explained by
differences in genetic background we searched for alleles with
large frequency differences between these populations that also
have an incidence on susceptibility to PCa.
In a preliminary screening of 21 ancestry informative markers
(AIMs) on chromosome 12 in 368 African American PCa cases
and controls we found an indication of association across an
extended region (from 23 Mb to 64 Mb). We increased the sample
size and coverage of the chromosome with additional AIMs and
SNPs in an attempt to narrow the region of interest and if possible,
identify the causal variant. Special consideration was given to the
vitamin D receptor (VDR, OMIM*601769) gene, located on
chromosome 12q13.11, as it is a likely candidate and previous
reports have revealed an association between polymorphisms in
this gene and PCa [4].
Materials and Methods
Subjects
Five hundred and fifty unrelated African American cases and
controls were included in the study. Recruitment for both patients
and healthy controls took place at Howard University Hospital in
Washington, D.C, through the Division of Urology and prostate
cancer screening programs.
PSA levels and other clinical assessments were determined for
all PCa cases and all controls. Prostate cancer patients did not
have more than one first degree relative with PCa. All controls had
a normal digital rectal examination.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16044Disease aggressiveness was defined based on TNM stage and
Gleason grade. Low aggressiveness was determined by a T
category,T2c and a Gleason grade ,7. Conversely, high
aggressiveness was characterized by a T category $T2c and a
Gleason grade $7. The study was approved by Howard
University and the University of Chicago hospitals Institutional
Review Board and by all participants, who provided written
informed consent.
Genomic DNA was obtained from peripheral blood samples
using standard techniques.
Genotyping
A set of 124 ancestry informative markers (AIMs) located on
chromosome 12, most of which were selected from a published
admixture map tailored for African Americans [5], were
genotyped in cases and controls and utilized to estimate local
ancestry. In addition, individual admixture proportions were
estimated using a set of 103 genome-wide AIMs chosen from the
same panel. Individuals belonging to each parental population, i.e.
HapMap Yoruba (YRI) and CEPH (CEU), were also typed for
these markers.
In addition, we genotyped fifteen SNPs in two genes that are
involved in vitamin D metabolism, eleven on the vitamin D
receptor (VDR) and four on CYP27B1 (OMIM*609506).
Finally, genotypes for a further set of 55 SNPs on chromosome
12 were collected and analysed in an attempt to circumscribe the
associated regions to specific genes.
The Illumina BeadLab platform [6] was used to genotype all
AIMs in this project. VDR, CYP27B1 and all SNPs used for finer
mapping were assayed with the Sequenom MassArray platform
[7].
All physical positions and SNP details reported in the current
study were based on NCBI genome build 36 and dbSNP build
130.
Data analysis
The program STRUCTURE v2.2 [8] was run to estimate
individual and locus-specific ancestry. For our analysis the number
of parental populations was set at two. Runs consisted basically of
30000 burn-ins and 70000 iterations, and 5000 admixture burn-
ins when necessary. To collect data on site-by-site (local) ancestry
we used the linkage model, whereas a model that uses population
information from parental individuals’ genotypes was selected to
obtain individual ancestry proportions.
Linkage disequilibrium (LD) patterns along chromosome 12
were examined with the program Haploview v4.2 [9]. Selection of
tagSNPs was also done with Haploview using the YRI as the
reference population, pairwise tagging and a r
2 threshold of 0.8.
Binary logistic regression was used to estimate odds ratios (OR)
and 95% confidence intervals (CI) for the association of individual
markers and haplotypes with PCa with adjustment for age,
individual and local ancestry, via the programs SPSS v15 and
PLINK 1.07 [10]. Power calculations were performed with the
program Genetic Power Calculator [11].
Functional in silico analysis of gene variants to identify changes
in transcription factor binding sites, 59UTR and 39UTR motifs,
and conservation across species was carried out using the
programs included in the GenEpi toolbox [12].
Results
A total of 669 individuals were entered in the analysis, including
253 African American PCa patients, 297 African American
controls, 59 West Africans (HapMap YRI) and 60 Europeans
(HapMap CEU). Clinical and demographic characteristics of the
African American sample are presented in Table 1.
After eliminating markers with more than 50% missing
genotypes, less than 5% minor allele frequency (MAF), out of
Hardy-Weinberg equilibrium in controls (p,0.0005), closely
linked to others (,0.1 cM intermarker distance), 76 chromosome
12 AIMs and 88 genome-wide AIMs were analyzed (Tables S1
and S2).
Based on the power analyses we had on average ,70% power
(36–83%) to detect a genotype relative risk of 1.5 at an alpha level
of 0.05 for variants with a minor allele frequency $5%, assuming
the marker is in complete LD with the causal variant and a
prevalence of PCa in African Americans of 2.5%. If all variants
were considered, power decreased to ,60% (8–83%) due to the
fact that there is limited power to detect the effects of variants with
frequencies below 5% (22% power on average), see Table S3.
Ancestry and population structure
Using the set of genome-wide AIMs, mean allele frequency
difference (delta) between parental populations was found to be
74%, extending from 55% to 96% (Table S2). STRUCTURE
runs established two as the most probable number of clusters
within African Americans, irrespective of status, indicating the
presence of population stratification. Average European individual
ancestry (6 sd) was 22617% for the whole sample, similar to
previously reported estimates for this population [13]. PCa cases
had on average higher West African ancestry than controls (79%
vs 77%) although the difference was not significant (Table 1).
Patients were significantly older than controls (p,0.001, Table 1).
Association with disease status
Our initial analysis using 242 cases and 126 controls found that
three out of 21 AIMs were significantly associated with disease
status after adjustment for age and individual ancestry (p,0.05,
Table 2), while another AIM was close to significance (rs1963562,
p=0.07).
In order to further investigate these association signals we
expanded the chromosome 12 AIM set with 75 additional
polymorphisms and increased the sample size to a total of 550
individuals. Mean allele frequency difference between West
Africans and Europeans for this enlarged set of AIMs was 70%
(range: 24%–95%), and the average distance between markers was
1.25 Mb (Table S1). Coverage of the chromosome extended from
0.2 Mb to 131.2 Mb. Very few markers of this AIM panel are in
LD across the region, and those that do show low R
2 values. This
is expected to some extent as variants were selected to ensure the
absence of LD in the parental populations.
Table 1. Sample description.
cases controls p-value
N 253 297
mean age (sd) 65.9 (9.3) 58.9 (11.0) ,0.001
mean PSA (sd) 85.8 (393.9) 4.9 (15.0) 0.002
mean African ancestry (% 6 sd) 79.0 (16.3) 77.2 (18.2) 0.24
PCa aggressiveness
low (%) 82 (42.3) -
high (%) 112 (57.7) -
doi:10.1371/journal.pone.0016044.t001
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alpha level of 0.05, adjusting for age and individual ancestry,
although none achieved significance if applying a Bonferroni
correction for multiple testing (p,0.0007, Table S1). Interestingly,
for all loci, the most frequent allele among Europeans was also the
allele confering risk for PCa.
We selected 55 extra SNPs within the associated regions and
neighbouring candidate genes to try to pinpoint the source of the
association signal. Preference was given to tagSNPs as defined by
the program Haploview in the YRI population. This was done in
two stages, 20 SNPs were typed and analysed first and, based on
these and earlier results, 35 more variants were added, particularly
in the genes TMTC1, HMGA2 (OMIM*600698) and PAWR
(OMIM*601936), which displayed the strongest association with
PCa (Tables S1 and S4). Six SNPs were invariant in this
population whilst three were out of Hardy-Weinberg equilibrium
(p,0.002), therefore 46 polymorphisms were included in the final
analysis, of which four were significantly associated with PCa (one
in HMGA2 and three in PAWR). We did not pursue the HMGA2
association any further since rs17179670 is an intronic variant, is
the only polymorphism associated to disease within this gene and
the association signal is not particularly strong (p=0.03).
The PAWR gene region
Following all rounds of analysis rs12827748, located upstream of
the PAWR gene, remained the most significantly associated SNP,
even after adjustment for age and individual ancestry (p,0.01). This
SNP shows a large frequency difference between European and West
African populations (C allele: 0.63 vs 0.01, respectively), whereas the
frequency of the same allele in PCa cases is 0.18 compared to 0.11 in
controls (Table S4). To eliminate added confounding by ancestry we
included local ancestry estimates in the regression model.
Local ancestry at rs12827748 was assessed using the AIM
rs10778691, which was the closest one to rs12827748 (distant
,130 kb), and revealed that the probability of two European
chromosomes at this locus was greater in cases than in controls,
although the result was not significant (8.3% vs 7.6%, p=0.74).
Additional adjustment for local ancestry did not eliminate the
significance of the association between rs12827748 and PCa (OR
1.6; 95% CI, 1.1–2.4; p=0.02, Table 3).
Two other PAWR SNPs were also significant (rs8176908,
rs8176882, p,0.05, Tables 3 and S4), the minor alleles are completely
absent in European populations and have a lower than 10% frequency
among West Africans. Yet, when all three markers are included in the
logistic regression, with age, individual and local ancestry as covariates,
only rs12827748 exhibits a significant association (p=0.03). Linkage
disequilibrium is strong between rs8176908 and rs8176882 but weaker
between any of these and rs12827748 (data not shown).
Haplotypes constructed using the three PAWR polymorphisms
showed a strong protective effect of the TGG haplotype
(p=1.7610
24) whereas the haplotypes that included all European
alleles (i.e. alleles that have a higher frequency in European than in
West African populations, CGG) or all West African alleles (TCT)
significantly increased the risk of disease (Table 4). Only the TGG
haplotype remained significant after correction for multiple testing
by permutation analysis.









b cases controls p-value
c
rs989278 23773750 SOX5 intron 7 C/G 0.08 0.34 0.33 0.48
rs1993973 26201374 - G/A 0.63 0.45 0.38 0.004
rs1027089 26362337 - C/G 0.33 0.16 0.14 0.82
rs895964 26749333 ITPR2 intron 10 G/A 0.36 0.21 0.26 0.98
rs1010096 27735497 PPFIBP1 intron 28 C/T 0.32 0.44 0.43 0.11
rs1561131 29199198 - C/T 0.39 0.52 0.48 0.40
rs1843321 30245161 - C/T 0.57 0.37 0.41 0.04
rs1963562 36949163 - C/T 0.39 0.11 0.10 0.07
rs870431 37239340 - A/G 0.55 0.15 0.14 0.64
rs278906 39704904 CNTN1 intron 21 C/T 0.24 0.17 0.23 0.34
rs180438 45473527 SLC38A4 intron 2 G/A 0.67 0.23 0.24 0.11
rs739857 46254553 - A/C 0.40 0.14 0.11 0.52
rs1235153 46396592 P11 intron 5 C/T 0.05 0.01 0.00 0.64
rs615382 48699178 RACGAP1 intron 3 C/A 0.73 0.32 0.28 0.11
rs303810 50449515 SCN8A intron 18 T/C 0.49 0.48 0.47 0.96
rs585224 51209139 - A/G 0.51 0.28 0.23 0.004
rs1683151 52232486 ATF7 intron 5 C/G 0.51 0.11 0.09 0.99
rs1867299 52616242 - T/C 0.50 0.30 0.33 0.92
rs1078109 56272633 PIP4K2C intron 2 G/A 0.07 0.01 0.01 0.27
rs1157239 63814994 - G/A 0.52 0.32 0.27 0.80
rs343087 64547191 HMGA2 intron 4 A/G 0.78 0.19 0.16 0.85
amajor/minor allele assignment based on frequencies found in West Africans. Minor allele frequency is given.
bdelta=allele frequency difference between West African and European populations.
cp-value after adjustment for age and individual ancestry. Bold: SNPs associated with PCa, p,0.05.
doi:10.1371/journal.pone.0016044.t002
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gene function and found no disruption of transcription factor
binding sites or other regulatory effects. This is an intergenic SNP
that lies between PAWR and PPP1R12A and it may be in linkage
disequilibrium with functional variants in either gene, although
PAWR as a tumor suppressor is a more likely candidate. Never-
theless, LD patterns in HapMap populations CEU and YRI show
that rs12827748 can be found within a large block that includes all
of PAWR and its upstream region with a clearcut separation from
the block that contains PPP1R12A.
As expected, we noted that carriers of the rs12827748 C allele
displayed significantly higher mean European ancestry than
individuals with the TT genotype (0.30 vs 0.20, p,0.005), yet
there were no differences in ancestry between cases and controls
within each genotype group. However, if individuals are selected
based on local ancestry levels, for instance by restricting the
sample to those individuals with a higher than 95% probability of
having two European chromosomes at rs10778691 (N=32) or to
those carrying the rs12827748 CC genotype (N=21), cases show
a significantly elevated global West African ancestry (54–66% vs
32–34% in controls), although it is still low with respect to the
average of the unselected sample (78%). In spite of sample sizes
being quite small the differences are significant (p=0.03 and 0.01).
This suggests that there likely are additional factors inherited from
the West African ancestor that predispose to PCa.
Vitamin D related genes: VDR and CYP27B1
The active form of vitamin D (1,25(OH)2D3) reduces prolifer-
ation and promotes differentiation, and has been implicated in
cancers of the colon, breast and prostate. At the same time it has
been reported that individuals of West African descent have
approximately twofold lower levels of serum vitamin D (25(OH)D,
the major circulating metabolite) than those of predominantly
European ancestry [14], which may imply less protection from
cancer for the former. It has been suggested that polymorphic
variation within genes in the vitamin D pathway, such as VDR,
may contribute to the observed disparities in PCa rates between
populations of different origins.
Several studies have examined variation in VDR in search for an
association with different types of cancer. There are six commonly
studied polymorphisms in VDR: Cdx2 variant in the promoter
(rs11568820), FokI on exon 2 (rs2228570), BsmI on intron 8
(1544410), ApaI also on intron 8 (rs7975232), TaqI on exon 9
(rs731236), and the poly-A mononucleotide repeat at the 39UTR
of the gene. TaqI is in strong LD with the other markers in the
region (BsmI, ApaI and the poly-A microsatellite). Polymorphisms
in the 59 regulatory region are known to affect the transcriptional
activity of the gene whereas polymorphisms in the 39UTR have
been linked to the stability of mRNA [15]. Results for PCa have
been inconsistent with some studies showing positive associations
and others postulating no effects [16–19]. An association with
advanced PCa has also been reported, i.e. Gleason grade $7 [20].
Since two of the genes in the vitamin D pathway, namely VDR
and CYP27B1, are located on chromosome 12, we examined them
more closely by typing a few SNPs in them. CYP27B1 encodes the
enzyme 1-a-hydroxylase which catalyzes the conversion of
25(OH)D into 1,25(OH)2D3. Polymorphic variants in this gene
have been examined but found not to be associated with PCa [21].
Details of the SNPs typed are given in Table 5. Association with
disease was seen for two closely linked VDR SNPs, rs731236 (TaqI)
and rs7975128 (p,0.05, Tables 3 and 5), and their haplotypes
(Table 6). However, adjustment by age and individual ancestry
removed the significance of the associations. No effect of CYP27B1
variants on PCa risk was evident in this study.
Discussion
We have screened chromosome 12 in the search for alleles that
predispose African Americans for the onset and development of
Table 3. Odds ratios and 95% confidence intervals of PAWR and VDR SNPs significantly associated with prostate cancer.
PAWR risk allele OR 95% CI p-value adj OR 95% CI p-value
rs8176908 T 1.7 1.1–2.6 0.03 1.7 1.1–2.8 0.03
rs8176882 C 2.2 1.0–4.8 0.04 2.8 1.2–6.3 0.02
rs12827748 C 1.6 1.1–2.2 0.01 1.6 1.1–2.4 0.02
VDR risk allele OR 95% CI p-value adj OR 95% CI p-value
rs731236 C 1.3 1.0–1.8 0.04 1.3 1.0–1.7 0.11
rs7975128 A 1.4 1.1–1.8 0.02 1.3 1.0–1.7 0.07
Odds ratios per each additional risk allele, adjusted by age, individual and local ancestry for PAWR, and age and individual ancestry for VDR. rs8176908 and rs8176882
were tested as GG vs GT/TT and GG vs GC/CC, respectively, as they were rare SNPs.
doi:10.1371/journal.pone.0016044.t003
Table 4. PAWR haplotypes and prostate cancer risk.
haplotype cases controls OR 95% CI p-value adj OR 95% CI p-value
PAWR-H1 TGG 0.73 0.83 0.6 0.4–0.8 7.8E-05 0.5 0.4–0.7 1.7E-04
PAWR-H2 CGG 0.18 0.11 1.6 1.1–2.2 0.01 1.7 1.1–2.5 0.01
PAWR-H3 TGT 0.06 0.04 1.5 0.8–2.6 0.18 1.4 0.8–2.6 0.24
PAWR-H4 TCT 0.03 0.01 2.6 1.1–6.1 0.03 3.0 1.2–7.6 0.02
SNPs: rs12827748–rs8176882–rs8176908. Omnibus test: p=0.001. Odds ratios adjusted by age, individual and local ancestry.
doi:10.1371/journal.pone.0016044.t004
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incidence and mortality between African Americans and European
Americans. After carefully controlling for the effects of individual
and local ancestry we identified a polymorphism (rs12827748)
located upstream of the PAWR gene that significantly increased
susceptibility for PCa. The C allele, which confers risk, is rare in
West Africans but is the major allele in European populations. Two
additional PAWR SNPs (one intronic, one synonymous) were also
associated withPCainthesinglemarkeranalysisbuttheinclusionof
the three polymorphisms in the regression model eliminated all
significance except for rs12827748. However, since the latter two
variants are only present in populations of West African descent
they may also represent PCa risk factors that because of their lower
frequencies are not detected as independently significant signals.
There is then the possibility that this region harbors susceptibility
factors from European as well as West African origin, and in an
admixed population such as African Americans both of them could
be at work.
It is also interesting to note that all of the associated SNPs were
in fact low frequency variants with frequencies around or below
10% in controls. Odds ratios corresponding to these variants
ranged from 1.6 to 2.8, higher than those usually reported in
genome-wide association studies. Because of the relatively small
size of our study there is not enough power to detect the effect of
rare variants (i.e. those with frequencies lower than 1%) and
therefore cannot disregard them as potential PCa causative
factors. Similarly, the importance of variants with frequencies
below 5% may have been underestimated because of inadequate
power.
The PAWR or prostate apoptosis response gene is located on
chromosome 12q21 and is highly expressed in the prostate. It
promotes apoptosis and causes tumor regression, and its
downregulation is apparent during tumorigenesis [22]. However,
loss of PAWR is not enough to cause PCa in PAWR null mice but
does so when coupled with concomitant PTEN heterozygosity
[23]. Our results suggest that PAWR may be a low penetrance PCa
susceptibility gene and deserves further examination in other
populations and with respect to other PCa related phenotypes.
The relevance of these findings will, however, only be determined
by their replication in subsequent studies as we cannot ignore the
fact that studies with small sample sizes are at a higher risk of
reporting false positive associations [24].
The limited number of cases and controls also affected our
ability to conduct a formal admixture mapping study on
chromosome 12 as there is reduced power to detect a less than
2-fold risk due to ancestry [25].
We detected a marginally significant association of PCa with
two SNPs in the VDR gene, including the TaqI polymorphism.









rs731236 46525024 VDR T/C 0.33 0.27 0.04 I352I (TaqI)
rs7975128 46532095 VDR G/A 0.33 0.27 0.02 intron 8
rs2229828 46537572 VDR C/T 0.02 0.03 0.29 S148S
rs2248098 46539623 VDR C/T 0.45 0.41 0.27 intron
rs2228570 46559162 VDR G/A 0.20 0.20 0.80 T1M (FokI)
rs2254210 46559981 VDR G/A 0.34 0.34 1.00 intron
rs11574038 46563420 VDR G/A 0.04 0.03 0.57 intron
rs1989969 46564277 VDR C/T 0.43 0.43 0.85 intron
rs12581281 46581400 VDR C/T 0.03 0.05 0.15 intron
rs12721377 46581618 VDR A/G 0.03 0.02 0.22 intron
rs11568820 46588812 VDR A/G 0.21 0.22 0.91 promoter (Cdx2)
rs4646537 56443548 CYP27B1 A/C 0.07 0.06 0.47 intron
rs3782130 56448165 CYP27B1 C/G 0.10 0.12 0.38 upstream
rs10877012 56448352 CYP27B1 G/T 0.11 0.12 0.37 upstream
rs703842 56449006 CYP27B1/METTL1 T/C 0.29 0.31 0.55 upstream
amajor/minor allele assignment based on frequencies found in West Africans. Minor allele frequency is given. Bold: SNPs associated with PCa, p,0.05.
doi:10.1371/journal.pone.0016044.t005
Table 6. VDR haplotypes and prostate cancer risk.
haplotype cases controls OR 95% CI p-value adj OR 95% CI p-value
VDR-H1 TG 0.56 0.64 0.7 0.6–1.0 0.02 0.8 0.6–1.1 0.12
VDR-H2 CA 0.23 0.18 1.4 1.0–1.9 0.06 1.3 0.9–1.9 0.11
VDR-H3 TA 0.11 0.10 1.2 0.8–1.8 0.42 1.1 0.7–1.7 0.75
VDR-H4 CG 0.10 0.10 1.1 0.7–1.8 0.67 1.0 0.6–1.7 0.94
SNPs: rs731236–rs7975128. Omnibus test: p=0.15. Odds ratios adjusted by age and individual ancestry.
doi:10.1371/journal.pone.0016044.t006
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16044Contrary to what has been found in a recent meta-analysis the
minor allele (C=t) at TaqI was the risk allele in our study,
although the meta-analysis significant association was identified by
pooling together European, African and Asian populations [4].
However, a closer look at the data stratified by ethnicity indicates
that whereas the C allele appears to be protective in Europeans
and Asians it seems to confer risk in populations of African descent
[4]. Most of the studies that analyzed TaqI in Europeans did not
find a significant effect or reported that the major (T) allele
increased susceptibility to PCa [26][27]. On the other hand,
studies of VDR polymorphisms in African Americans with PCa
are fairly limited, the majority with small sample sizes and
consequently inconclusive with respect to the role of TaqI [26].
Finally, it is important to emphasize that the careful genome-
wide evaluation of the ancestral origins of an admixed population
such as African Americans represents a valuable means of
unraveling the genetic risk factors that are likely to contribute to
the existence of health disparities.
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